MEDIGARD LIMITED (ASX.MGZ)

Shareholders in this company should consider crystallising a capital loss in 2023/24 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

delisted from the close of trading on Friday, 26 February 2021, pursuant to Listing rule 17.15.

we understand the company failed to pay its annual listing fees by close of business on Friday, 26 February 2021

Under Listing Rule 17.6, any entity (if not already suspended) that has not paid its annual listing fees by close of business on Friday, 19 February 2021 will have its securities suspended from official quotation before the commencement of trading on Monday, 22 February 2021. The company has not paid the second instalment of its annual listing fees in respect of the year ending 30 June 2021 but the securities are already suspended from official quotation.

On 3 December 2020, we lodged an application in the Federal Court to adjourn the time for the convening of the second meeting of creditors to 9 April 2021. The Order was granted on 7 December 2020. The reason the second meeting has been adjourned is to consider further and potentially assist with facilitating a (as yet draft) proposal received to recapitalise the company.

The company wishes to correct the date of the original announcement date. The announcement lodged on 12 November 2020 incorrectly showed the date of announcement as 12 November 2012.

The company releases a Letter to Shareholders.

The company lodges its Preliminary Final Report.

The company releases a notice of Proposed issue of Securities - MGZ.

Project Licence payments and possible termination. Company is assessing other activities and funding arrangements.

The company lodges its Appendix 4C - quarterly.

The company lodges its Half Yearly Report and Accounts.

The company issues a Response to ASX Appendix 4C Query.

The company lodges its Appendix 4C - quarterly.

The company has completed the issue of 32,167,709 fully paid ordinary shares to related parties at a deemed issue price of $0.014 per share in settlement of loan balances of $450,347.94 due to the related parties. This debt reduction by the issue of shares is in addition to a reversal of accrued interest on the related party loans of $95,722 and the previous reduction of $615,000 convertible note debt as announced on 28 August 2019 and completed on 10 September 2019.

The company has lodged a Cleansing Prospectus with ASIC today.

The company releases its constitution (amended at AGM 13 November 2019).

The company releases the results of its meeting.

The company releases its Chairman's Address to Shareholders.

The company releases its Corporate Governance Statement 2019.

The company issues a response to ASX Appendix 4C Query.

The company lodges its Appendix 4C - quarterly.

The company's AGM will be held at 10:30am (Brisbane time) on 13 November 2019 at Southport Yacht Club, 1 Macarthur Parade, Main Beach, Queensland 4217.

The company releases a cleansing prospectus for an issue of up to 1,000 new shares at an issue price of 1.4 cents ($0.014) per share to raise $14 before costs of the issue. The offer is only made to and able to be accepted by invitees determined by the company who receive a personalised application form.

The company lodges its Annual Report to shareholders.

The company lodges its Preliminary Final Report.

The company releases its Appendix 4G.

The company hsa agreed terms with Sol Millennium Medical to cancel all the company's convertible notes and the directors have agreed, subject to shareholder approval, to convert all director loans to shares. Both parties have agred to extinguish the full note amount of AU$615,000 by the transfer of intellectual property covered by the existing license agreement to Sol-Millennium; issue of 5 million fully paid ordinary shares to Sol-Millennium, and; cancellation of the licence agreement and associated option agreement between Medigard and Sol-Millennium.

The company lodges its Appendix 4C - quarterly.

The company has conducted productive discussions with the holder of convertible notes on issue by the Company. The holder has indicated that the notes will not be settled by the issue of shares in Medigard and, as an interim measure, the holder has extended the due date for settlement of the notes to 30 June 2019 pending further discussions on settlement terms and timing. The directors have agreed in principle, subject to arranging a viable recapitalisation and shareholder approval, to convert their existing loans to the company, of approximately $393,000, into shares. An escalation of activity in the KT009 development program requires additional funding which is also being considered as part of the current recapitalisaton

The company lodges an Appendix 4C - quarterly.

The ASX had reviewed the Company's Half Year Accounts and formed the view that the Company's level of operations and financial conditions were not considered adequate to warrant the continued quotation of its securities under Listing Rules 12.1 and 12.2. The suspension will continue until the company is able to demonstrate compliance with the said listing rules. Also, the company has a development program underway for the KT009 product. An escalation of activity in this requires additional funding.

The securities of Medigard Limited will be suspended from quotation immediately in accordance with Listing Rule 17.3, as ASX has determined that MGZ's operations and financial conditions are not adequate to warrant the continued quotation of its securities and therefore it is in breach of Listing Rules 12.1 and 12.2. The suspension will continue until MGZ is able to demonstrate compliance with Listing Rules 12.1 and 12.2.

listed entity carried for record purposes only